GlassScriptPhysician profile
Eileen Aversa
NPI 1275582157
$4,615.75
in general payments reported to CMS, 2019-2025
21 companies · $768 in 2025
The $768 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,078 · 2023: $746 · 2024: $1,023 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $967.90 | 2022 | |
| Lilly USA, LLC | $674.38 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $457.15 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $279.24 | 2022-2024 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $259.62 | 2023-2025 | Tremfya, Simponi Aria |
| Leo Pharma INC. | $253.64 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $232.26 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $167.90 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $160.77 | 2024-2025 | |
| Incyte Corporation | $155.92 | 2022-2025 | Opzelura |
| Abbvie INC. | $155.83 | 2022-2025 | |
| Epi Health, LLC | $145.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $138.98 | 2022-2025 | |
| Journey Medical Corporation | $122.29 | 2022-2024 | |
| Amgen INC. | $118.75 | 2023 | Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $77.19 | 2022-2024 | |
| Galderma Laboratories, L.P. | $70.18 | 2023-2025 | Nemluvio, Twyneo, Epsolay |
| Ucb, INC. | $49.75 | 2025 | Bimzelx |
| Almirall LLC | $43.62 | 2022-2024 | Seysara |
| Organon LLC | $42.54 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.43 | 2022-2024 | Jublia, Duobrii, Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Aversa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.